Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146

NCT01074970 is registered in ClinicalTrials.gov with Hoosier Cancer Research Network as lead sponsor.

NCT NCT01074970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01074970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146
Lead sponsor
Hoosier Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2010
Completion date
December 15, 2018
Enrollment
135 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer